PCK2 and nasopharyngeal carcinoma: In a retrospective induction chemotherapy cohort of patients with NPC from our center (n = 182; Sun Yat-sen University Cancer Center (SYSUCC) NPC cohort-1) (Supplementary Table 1), we performed IHC staining of samples with anti-pACSL4(T679) or anti-PCK2 antibodies (Supplementary Fig. 9a), and we observed a strong correlation between the signal intensity of PCK2 staining and that of pACSL4(T679) staining (Extended Data Fig. 10a).